Curevac muddies the Moderna/Arbutus waters further
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
The Covid-19 vaccine battle just got interesting
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
A poor quarter for Roche leads to muted expectations
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
Covid-19 vaccine contest turns to T-cell responses
The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
Synairgen joins the 2020 coronavirus winners club
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
US pursues pooled testing for Covid-19, and Quest benefits
Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
Moderna's Covid-19 vaccine shows promise
But the trade-off between efficacy and tolerability could limit mRNA-1273’s use to those who need it least.
Venture investors: biotech's preppers?
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.
Biopharma shares shake off the pandemic
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Astra shakes things up with Covid-19 pricing disclosure
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
Curevac muddies the Moderna/Arbutus waters further
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
The Covid-19 vaccine battle just got interesting
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
A poor quarter for Roche leads to muted expectations
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
